Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study

Article Hematology

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs et al.

Summary: Results from two parallel phase 2 trials comparing unrelated umbilical cord blood transplantation and HLA-haploidentical bone marrow transplantation showed similar 2-year progression-free survival rates, but lower overall survival and higher nonrelapse mortality rates after umbilical cord blood transplantation compared to haploidentical bone marrow transplantation.

BLOOD (2021)

添加到收藏夹

Article Hematology

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Mitchell E. Horwitz et al.

Summary: The study demonstrated that transplantation with omidubicel resulted in shorter time to neutrophil engraftment, faster platelet recovery, lower incidence of infections, and more time spent out of hospital compared to standard umbilical cord blood transplantation. Differences in GVHD and survival were not statistically significant between the two groups. The results suggest that omidubicel may be considered as a new standard of care for adult patients eligible for UCBT.

BLOOD (2021)

添加到收藏夹

Article Hematology

A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma

Takashi Tanaka et al.

Summary: The study confirmed that HLA-haploidentical PBSCT with PTCy as GVHD prophylaxis is a safe and effective option for patients with aggressive ATL, with high survival rates and relatively high incidence of GVHD, resulting in an overall high probability of survival for patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology